1. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society on Intensive Care Medicine (ESICM). Eur J HeartFail. 2008; 10(10): 933 - 989.
2. Фомин И.В. Артериальная гипертония в Российской Федерации - последние 10 лет. Что дальше? Сердце. 2007; 6(3): 1 - 6.
3. Фомин И.В. Эпидемиология хронической сердечной недостаточности в Российской Федерации. В кн.: Хроническая сердечная недостаточность [Агеев Ф.Т. и соавт.] - М.: ГЭОТАР-Медиа, 2010. - с. 7 - 77.
4. Cleland J.G., Swedberg K., Follath F. et al. The EuroHeart Failure survey programme a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003; 24(5): 442 - 463.
5. Lam C.S.P., Solomon S.D. The middle child in heart failure: heart failure with mid-range ejection fraction (40 - 50%). Eur J Heart Fail 2014; 16: 1049 - 1055.
6. Щербинина Е.В., Бадин Ю.В., Вайсберг А.Р., и др. Динамика этиологических причин формирования ХСН в репрезентативной выборке Нижегородской области за 9 лет наблюдения (1998 - 2007 гг.). Всероссийская конференция ОССН: "Сердечная недостаточность, 2007 год" - М., 2007. - с. 38.
7. Фомин И.В., Бадин Ю.В., Егорова И.С., Щербинина Е.В. Гендерные различия в распространенности сердечно-сосудистых заболеваний (данные когортного исследования репрезентативной выборки Нижегородской области 1998 - 2002 гг.). Проблемы женского здоровья. 2006; 1 (1): 37 - 40.
8. Ho K.K., Pinsky J.L., Kannel W.B., Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22 (4 Suppl A):6A - 13A.
9. Owan T.E., Hodge D.O., Herges R.M., Jacobsen S.J., Roger V.L., Redfield M.M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251 - 259.
10. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 2012; 33: 1750 - 1757.
11. Hogg K., Swedberg K., McMurray J. Heart Failure with preserved left ventricular systolic function. Epidemiology, Clinical Characteristics, and Prognosis. J Am Coll Cardiol. 2004; 43(3): 317 - 327.
12. Агеев Ф.Т. Влияние современных медикаментозных средств на течение заболевания "качество жизни" и прогноз больных с различными стадиями хронической сердечной недостаточности. Автореф. Дисс. Докт., Москва, 1997.
13. Терещенко С.Н., Жиров И.В., Нарусов О.Ю., Мареев Ю.В., Затейщиков Д.А., Осмоловская Ю.Ф., Овчинников А.Г., Самко А.Н., Насонова С.Н., Стукалова О.В., Саидова М.А., Скворцов А.А., Шария М.А., Явелов И.С. Диагностика и лечение хронической и острой сердечной недостаточности. Кардиологический вестник, 2016; N 2: 3 - 33.
14. McMurray J. Clinical practice. Systolic heart failure. N Engl J Med. 2010; 362(3): 228 - 238.
15. Chen J., Normand S.L., Wang Y., Krumholz H.M. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998 - 2008. JAMA. 2011; 306(15): 1669 - 1678.
16. Dunlay S.M., Redfield M.M., Weston S.A. et al. Hospitalizations after heart failure diagnosis a community perspective. J Am Coll Cardiol. 2009; 54(18): 1695 - 1702.
17. Senni M., Gavazzi A., Oliva F., at al. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry. Intern J Cardiol 2014; 173: 163 - 9.
18. Cowie M.R., Fox K.F., Wood D.A. et al. Hospitalization of patients with heart failure: a population-based study. Eur Heart J. 2002; 23(11): 877 - 885.
19. McAlister F.A., Teo K.K., Taher M. et al. Insights into the contemporary epidemiology and outpatient management of congestive heart failure. Am Heart J. 1999; 138 (1 Pt 1): 87 - 94.
20. Беленков Ю.Н., Овчинников А.Г., Агеев Ф.Т., Сербул В.М. Гипертрофия левого желудочка: роль ренин-ангиотензиновой системы. Кардиоваскулярная терапия и профилактика 2008; N 2: 98 - 108. (http://www.fesmu.ru/elib/Article.aspx?id=179627)
21. Овчинников А.Г., Агеев Ф.Т., Свирида О.Н. (http://www.fesmu.ru/elib/Article.aspx?id=179627) Патогенетический подход к терапии пациентов с хронической сердечной недостаточностью и сохраненной систолической функцией левого желудочка. Кардиологический вестник 2011; N 1: 33 - 39. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
22. Pocock S.J., Wang D., Pfeffer M.A. et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006; 27(1): 65 - 75. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
23. Komajda M., Carson P.E., Hetzel S. et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail. 2011; 4(1): 27 - 35. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
24. Ketchum E.S., Levy W.C. Establishing prognosis in heart failure: a multimarker approach. Prog Cardiovasc Dis. 2011; 54(2): 86 - 96. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
25. Ho K.K., Anderson K.M., Kannel W.B. et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993; 88(1): 107 - 115. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
26. Даниелян М.О. Прогноз и лечение хронической сердечной недостаточности (данные 20-и летнего наблюдения). Автореф. дис. канд. мед. наук. Москва. 2001. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
27. Бадин Ю.В., Фомин И.В. Выживаемость больных ХСН в когортной выборке Нижегородской области (данные 1998 - 2002 годов.). Всероссийская конференция ОССН: "Сердечная недостаточность, 2005 год" - М., 2005. - с. 31 - 32. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
28. Wedel H., McMurray J.J., LindbergMetal. Predictors of fatal and nonfatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal proB-type natriuretic peptide. Eur J Heart Fail. 2009; 11(3): 281 - 291. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
29. Allen L.A., Felker G.M., Pocock S. et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail. 2009; 11(2): 170 - 177. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
30. Jackson C.E., Solomon S.D., Gerstein H.C. et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 2009; 374(9689): 543 - 550. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
31. Felker G.M., Allen L.A., Pocock S.J. et al. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol. 2007; 50(1): 40 - 47. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
32. Беленков Ю.Н., Фомин И.В., Мареев В.Ю. и др. Первые результаты Российского эпидемиологического исследования по ХСН. Журнал Сердечная Недостаточность 2003; 4(1): 26 - 30. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
33. Агеев Ф.Т., Даниелян М.О., Мареев В.Ю. и др. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА-О-ХСН). Журнал Сердечная Недостаточность 2004; 5(1): 4 - 7. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
34. Агеев Ф.Т., Беленков Ю.Н., Фомин И.В. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации - данные ЭПОХА-ХСН. Журнал Сердечная Недостаточность 2006; 7(1): 112 - 115. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
35. Davie P., Francis C.M., Caruana L., Sutherland G.R., McMurray J.J. Assessing diagnosis in heart failure: which features are any use? QJM 1997; 90: 335 - 339. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
36. Mant J., Doust J., Roalfe A., Barton P., Cowie M.R., Glasziou P., Mant D., McManus R.J., Holder R., Deeks J., Fletcher K., Qume M., Sohanpal S., Sanders S., Hobbs FDR. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess 2009; 13: 1 - 207, iii. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
37. Oudejans I., Mosterd A., Bloemen J.A., Valk M.J., Van Velzen E., Wielders J.P., Zuithoff N.P., Rutten F.H., Hoes A.W. Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests. Eur J Heart Fail 2011; 13: 518 - 527. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
38. Fonseca C. Diagnosis of heart failure in primary care. Heart Fail Rev 2006; 11: 95 - 107. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
39. Kelder J.C., Cramer M.J., van Wijngaarden J., van Tooren R., Mosterd A., Moons KGM, Lammers J.W., Cowie M.R., Grobbee D.E., Hoes A.W. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation 2011; 124: 2865 - 2873. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
40. Roberts E., Ludman A.J., Dworzynski K., Al-Mohammad A., Cowie M.R., McMurray J.J.V., Mant J. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ 2015; 350: h910. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
41. Zaphiriou A., Robb S., Murray-Thomas T., Mendez G., Fox K., McDonagh T., Hardman S.M.C., Dargie H.J., Cowie M.R. The diagnostic accuracy of plasma BNP and NTpro мозговой натрийуретический пептид in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail 2005; 7: 537 - 541. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
42. Fuat A., Murphy J.J., Hungin A.P.S., Curry J., Mehrzad A.A., Hetherington A., Johnston J.I., Smellie W.S.A., Duffy V., Cawley P. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract 2006; 56: 327 - 333. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
43. Yamamoto K., Burnett J.C., Bermudez E.A., Jougasaki M., Bailey K.R., Redfield M.M. Clinical criteria and biochemical markers for the detection of systolic dysfunction. J Card Fail 2000; 6: 194 - 200. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
44. Cowie M.R., Struthers A.D., Wood D.A., Coats A.J., Thompson S.G., Poole-Wilson P.A., Sutton G.C. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1349 - 1353. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
45. Krishnaswamy P., Lubien E., Clopton P., Koon J., Kazanegra R., Wanner E., Gardetto N., Garcia A., DeMaria A., Maisel A.S. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 2001; 111: 274 - 279. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
46. Kelder J.C., Cramer M.J., Verweij W.M., Grobbee D.E., Hoes A.W. Clinical utility of three B-type natriuretic peptide assays for the initial diagnostic assessment of new slow-onset heart failure. JCardFail 2011; 17: 729 - 734 (http://www.fesmu.ru/elib/Article.aspx?id=242318)
47. van Riet E.E.S., Hoes A.W., Limburg A., Landman M.A.J., van der Hoeven H., Rutten F.H. Prevalence of unrecognized heart failure in older persons with shortness ofbreath on exertion. Eur J Heart Fail 2014; 16: 772 - 777. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
48. Kelder J.C., Cramer M.J., van Wijngaarden J., van Tooren R., Mosterd A., Moons K.G.M., Lammers J.W., Cowie M.R., Grobbee D.E., Hoes A.W. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation 2011; 124: 2865 - 2873. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
49. Davie A.P., Francis C.M., Love M.P., Caruana L., Starkey I.R., Shaw T.R., Sutherland G.R., McMurray J.J. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ 1996; 312: 222. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
50. Thomas J.T., Kelly R.F., Thomas S.J., Stamos T.D., Albasha K., Parrillo J.E., Calvin J.E. Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure.Am J Med 2002; 112: 437 - 445. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
51. Paulus W.J., Tschope C., Sanderson J.E., Rusconi C., Flachskampf F.A., Rademakers F.E., Marino P., Smiseth O.A., De Keulenaer G., Leite-Moreira A.F., Borbely A., Edes I., Handoko M.L., Heymans S., Pezzali N., Pieske B., Dickstein K., Fraser A.G., Brutsaert D.L. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28: 2539 - 2550. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
52. Marwick T.H., Raman S.V., Carrio' I., Bax J.J. Recent developments in heart failure imaging. JACC Cardiovasc Imaging 2010; 3: 429 - 439. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
53. Dokainish H., Nguyen J.S., Bobek J., Goswami R., Lakkis N.M. Assessment of the American Society of Echocardiography-European Association of Echocardiography guidelines for diastolic function in patients with depressed ejection fraction: an echocardiographic and invasive haemodynamic study. Eur J Echocardiogr 2011; 12: 857 - 864. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
54. Kirkpatrick J.N., Vannan M.A., Narula J., Lang R.M. Echocardiography in heart failure: applications, utility, and new horizons. J Am Coll Cardiol 2007; 50: 381 - 396. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
55. Nagueh S.F., Bhatt R., Vivo R.P., Krim S.R., Sarvari S.I., Russell K., Edvardsen T., Smiseth O.A., Estep J.D. Echocardiographic evaluation of hemodynamics in patients with decompensated systolic heart failure. Circ Cardiovasc Imaging 2011; 4: 220 - 227. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
56. Caballero L., Kou S., Dulgheru R., Gonjilashvili N., Athanassopoulos G.D., Barone D., Baroni M., Cardim N., Gomez de Diego J.J., Oliva M.J., Hagendorff A., Hristova K., Lopez T., Magne J., Martinez C., de la Morena G., Popescu B.A., Penicka M., Ozyigit T., Rodrigo Carbonero J.D., Salustri A., Van De Veire N., Von Bardeleben R.S., Vinereanu D., Voigt J-U, Zamorano J.L., Bernard A., Donal E., Lang R.M., Badano L.P., Lancellotti P. Echocardiographic reference ranges for normal cardiac Doppler data: results from the NORRE Study. Eur Heart J Cardiovasc Imaging 2015; 16: 1031 - 1041. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
57. Garbi M., McDonagh T., Cosyns B., Bucciarelli-Ducci C., Edvardsen T., Kitsiou A., Nieman K., Lancellotti P. Appropriateness criteria for cardiovascular imaging use in heart failure: report of literature review. Eur Heart J Cardiovasc Imaging 2015; 16: 147 - 153. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
58. Lang R.M., Badano L.P., Mor-Avi V., Afilalo J., Armstrong A., Ernande L., Flachskampf F.A., Foster E., Goldstein S.A., Kuznetsova T., Lancellotti P., Muraru D., Picard M.H., Rietzschel E.R., Rudski L., Spencer K.T., Tsang W., Voigt J-U. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015; 16: 233 - 270. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
59. Gimelli A., Lancellotti P., Badano L.P., Lombardi M., Gerber B., Plein S., Neglia D., Edvardsen T., Kitsiou A., Scholte AJHA, Schroder S., Cosyns B., Gargiulo P., Zamorano J.L., Perrone-Filardi P. Non-invasive cardiac imaging evaluation of patients with chronic systolic heart failure: a report from the European Association of Cardiovascular Imaging (EACVI). Eur Heart J 2014; 35: 3417 - 3425. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
60. Voigt J-U, Pedrizzetti G., Lysyansky P., Marwick T.H., Houle H., Baumann R., Pedri S., Ito Y., Abe Y., Metz S., Song J.H., Hamilton J., Sengupta P.P., Kolias T.J., d'Hooge J., Aurigemma G.P., Thomas J.D., Badano L.P. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. Eur.HeartJ. Cardiovasc. Imaging 2015; 16: 1 - 11. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
61. Cohen G.I., Pietrolungo J.F., Thomas J.D., Klein A.L. A practical guide to assessment of ventricular diastolic function using Doppler echocardiography. J Am Coll Cardiol 1996; 27: 1753 - 1760. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
62. Gilman G., Nelson T.A., Hansen W.H., Khandheria B.K., Ommen S.R. Diastolic function: a sonographer's approach to the essential echocardiographic measurements of left ventricular diastolic function. J Am Soc Echocardiogr 2007; 20: 199 - 209. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
63. Nagueh S.F., Appleton C.P., Gillebert T.C., Marino P.N., Oh J.K., Smiseth O.A., Waggoner A.D., Flachskampf F.A., Pellikka P.A., Evangelisa A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009; 10: 165 - 193. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
64. Nishimura R.A., Appleton C.P., Redfield M.M., Ilstrup D.M., Holmes D.R., Tajik A.J. Noninvasive doppler echocardiographic evaluation of left ventricular filling pressures in patients with cardiomyopathies: a simultaneous Doppler echocardiographic and cardiac catheterization study. J Am Coll Cardiol 1996; 28: 1226 - 1233. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
65. Ommen S.R., Nishimura R.A., Appleton C.P., Miller F.A., Oh J.K., Redfield M.M., Tajik A.J. Clinical utility of Doppler echocardiography and tissue doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Dopplercatheterization study. Circulation 2000; 102: 1788 - 1794 (http://www.fesmu.ru/elib/Article.aspx?id=242318)
66. Hawkins N.M., Petrie M.C., Jhund P.S., Chalmers G.W., Dunn F.G., McMurray J.J.V. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail 2009; 11: 130 - 139. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
67. Thomas J.T., Kelly R.F., Thomas S.J., Stamos T.D., Albasha K., Parrillo J.E., Calvin J.E. Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure. Am J Med 2002; 112: 437 - 445. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
68. Windecker S., Kolh P., Alfonso F., Collet J-P., Cremer J., Falk. V, Filippatos G., Hamm C., Head S.J., Juni P., Kappetein A.P., Kastrati A., Knuuti J., Landmesser U., Laufer G., Neumann F-J., Richter D.J., Schauerte P., Sousa Uva M., Stefanini G.G., Taggart D.P., Torracca L., Valgimigli M., Wijns W. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541 - 2619. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
69. Montalescot G., Sechtem U., Achenbach S., Andreotti F., Arden C., Budaj A., Bugiardini R., Crea F., Cuisset T., Di Mario C., Ferreira J.R., Gersh B.J., Gitt A.K., Hulot J-S., Marx N., Opie L.H., Pfisterer M., Prescott E., Ruschitzka F., Sabate' M., Senior R., Taggart D.P., van der Wall E.E., Vrints C.J.M., Zamorano J.L., Baumgartner H., Bax J.J., Bueno H., Dean V., Deaton C., Erol C., Fagard R., Ferrari R., Hasdai D., Hoes A.W., Kirchhof P., Knuuti J., Kolh P., Lancellotti P., Linhart A., Nihoyannopoulos P., Piepoli M.F., Ponikowski P., Sirnes P.A., Tamargo J.L., Tendera M., Torbicki A., Wijns W., Windecker S., Valgimigli M., Claeys M.J., Donner-Banzhoff N., Frank H., Funck-Brentano C., Gaemperli O., Gonzalez-Juanatey J.R., Hamilos M., Husted S., James S.K., Kervinen K., Kristensen S.D., Maggioni A. Pietro, Pries A.R., Romeo F., Ryde'n L., Simoons M.L., Steg P.G., Timmis A., Yildirir A. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J 2013; 34: 2949 - 3003. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
70. Roffi M., Patrono C., Collet J-P., Mueller C., Valgimigli M., Andreotti F., Bax J.J., Borger M.A., Brotons C., Chew D.P., Gencer B., Hasenfuss G., Kjeldsen K., Lancellotti P., Landmesser U., Mehilli J., Mukherjee D., Storey R.F., Windecker S. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2015; ehv320. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
71. Beller G.A., Heede R.C. SPECT imaging for detecting coronary artery disease and determining prognosis by noninvasive assessment of myocardial perfusion and myocardial viability. J Cardiovasc Transl Res 2011; 4: 416 - 424. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
72. Sicari R., Nihoyannopoulos P., Evangelista A., Kasprzak J., Lancellotti P., Poldermans D., Voigt J.U., Zamorano J.L. Stress Echocardiography Expert Consensus Statement-Executive Summary: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur Heart J 2009; 30: 278 - 289. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
73. Garnier F., Eicher J-C., Jazayeri S., Bertaux G., Bouchot O., Aho L-S., Wolf J-E., Laurent G. Usefulness and limitations of contractile reserve evaluation in patients with low-flow, low-gradient aortic stenosis eligible for cardiac resynchronization therapy. Eur J Heart Fail 2014; 16: 648 - 654 (http://www.fesmu.ru/elib/Article.aspx?id=242318)
74. Allman K.C., Shaw L.J., Hachamovitch R., Udelson J.E. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002; 39: 1151 - 1158. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
75. Ling L.F., Marwick T.H., Flores D.R., Jaber W.A., Brunken R.C., Cerqueira M.D., Hachamovitch R. Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction inducible ischemia versus hibernating myocardium. Circ Cardiovasc Imaging 2013; 6: 363 - 372. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
76. Bonow R.O., Maurer G., Lee K.L., Holly T.A., Binkley P.F., Desvigne-Nickens P., Drozdz J., Farsky P.S., Feldman A.M., Doenst T., Michler R.E., Berman D.S., Nicolau J.C., Pellikka P.A, Wrobel K., Alotti N., Asch F.M., Favaloro L.E., She L., Velazquez E.J., Jones R.H., Panza J.A. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med 2011; 364: 1617 - 1625. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
77. Gonzalez J.A., Kramer C.M. Role of imaging techniques for diagnosis, prognosis and management of heart failure patients: cardiac magnetic resonance. Curr Heart Fail Rep 2015; 12: 276 - 283. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
78. Hundley W.G., Bluemke D.A., Finn J.P., Flamm S.D., Fogel M.A., Friedrich M.G., Ho V.B., Jerosch-Herold M., Kramer C.M., Manning W.J., Patel M., Pohost G.M., Stillman A.E., White R.D., Woodard P.K., Harrington R.A., Anderson J.L., Bates E.R., Bridges C.R., Eisenberg M.J., Ferrari V.A., Grines C.L., Hlatky M.A., Jacobs A.K., Kaul S., Lichtenberg R.C., Lindner J.R., Moliterno D.J., Mukherjee D., Rosenson R.S., Schofield R.S., Shubrooks S.J., Stein J.H., Tracy C.M., Weitz H.H., Wesley D.J. ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American college of cardiology foundation task force on expert consensus documents. Circulation 2010; 121: 2462 - 2508. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
79. Moon J.C., Messroghli D.R., Kellman P., Piechnik S.K., Robson M.D., Ugander M., Gatehouse P.D., Arai A.E., Friedrich M.G., Neubauer S., Schulz-Menger J., Schelbert E.B. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson 2013; 15: 92. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
80. Yoshida A., Ishibashi-Ueda H., Yamada N., Kanzaki H., Hasegawa T., Takahama H., Amaki M., Asakura M., Kitakaze M. Direct comparison of the diagnostic capability of cardiac magnetic resonance and endomyocardial biopsy in patients with heart failure. EurJHeartFail 2013; 15: 166 - 175. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
81. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVDinvestigators. N Engl J Med. 1991; 325(5): 293 - 302. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
82. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987; 316(23): 1429 - 1435. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
83. Garg R., Yusuf S., for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure JAMA. 1995; 273(18): 1450 - 1456. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
84. Pfeffer M.A., Braunwald E., Moye L.A. et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement Trial. The SAVE Investigators. N Engl J Med. 1992; 327(10): 669 - 677. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
85. Kober L., Torp-Pedersen C., Carlsen J.E. et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995; 333(25): 1670 - 1676. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
86. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993; 342(8875): 821 - 828. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
87. Packer M., Poole-Wilson P.A., Armstrong P.W., Cleland J.G., Horowitz J.D., Massie B.M., 
L., Thygesen K., Uretsky B.F. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999 Dec 7; 100(23): 2312 - 8. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
88. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD investigators. N Engl J Med. 1992; 327(10): 685 - 691. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
89. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999; 353(9146): 9 - 13. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
90. MERIT-HF Study Group. Effects of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized International Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353(9169): 2001 - 2007. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
91. Packer M., Bristow M.R., Cohn J.N. et al, for the U. S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334(21): 1349 - 1355. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
92. Packer M., Coats A.J., Fowler M.B. et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001; 344(22): 1651 - 1658. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
93. Flather M.D., Shibata M.C., Coats A.J. et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005; 26(3): 215 - 225. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
94. Poole - Wilson P.A., Swedberg K., Cleland J.G. et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362(9377): 7 - 13. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
95. Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial. Lancet 2001; 357: 1385 - 1390. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
96. Gattis W.A., O'Connor C.M., Leimberger J.D. et al. Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. Am J Cardiol. 2003; 91(2): 169 - 174. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
97. Jondeau G., Neuder Y., Eicher J.C. et al. B-CONVINCED: Betablocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur Heart J. 2009; 30(18): 2186 - 2192. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
98. Pitt B., Zannad F., Remme W.J. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341(10): 709 - 717. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
99. Zannad F., McMurray J.J., Krum H. et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011; 364 (1): 11 - 21. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
100. Pitt B., Remme W., Zannad F. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348 (14): 1309 - 1321. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
101. Pitt B., White H., Nicolau J. et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J. Am Coll Cardiol. 2005; 46 (3): 425 - 431. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
102. Pitt B., Gheorghiade M., Zannad F. et al. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction < or = 30%. Eur J Heart Fail. 2006; 8 (3): 295 - 301. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
103. Juurlink D.N., Mamdani M.M., Lee D.S. et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004; 351 (6): 543 - 551. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
104. Faris R., Flather M., Purcell H., Henein M., Poole-Wilson P., Coats A. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomized controlled trials. Int J Cardiol 2002; 82: 149 - 158. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
105. Faris R.F., Flather M., Purcell H., Poole-Wilson P.A., Coats A.J. Diuretics for heart failure. Cochrane Database Syst Rev 2012; 2: CD003838. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
106. Dormans T.P., van Meyel J.J., Gerlag P.G. et al. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol. 1996; 28 (2): 376 - 382. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
107. Vargo D.L., Kramer W.G., Black P.K. et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther. 1995; 57 (6): 601 - 609. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
108. Patterson J.H., Adams K.F. Jr, Applefeld M.M. et al. for the Torasemide Investigators Group. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Pharmacotherapy. 1994; 14 (5): 514 - 521. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
109. Brater D. Torasemid: pharmacokinetic and clinical efficacy. Eur J Heart Fail. 2001;3 (Suppl G): 19 - 24. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
110. Cosin J., Diez J., Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002; 4 (4): 507 - 513 (http://www.fesmu.ru/elib/Article.aspx?id=242318)
111. Fortuno A., Muniz P., Ravassa S. et al. Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension. 1999; 34 (1): 138 - 143. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
112. Yamato M., Sasaki T., Honda K. et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ J. 2003; 67 (5): 384 - 390. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
113. McMurray J.J., Packer M., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R., Rouleau J.L., Shi V.C., Solomon S.D., Swedberg K., Zile M.R., PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993 - 1004. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
114. Pfeffer M.A., McMurray J.J., Velazquez E.J. et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003; 349 (20): 1893 - 1906. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
115. Granger C.B., McMurray J.J., Yusuf S. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003; 362 (9386): 772 - 776. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
116. Cohn J.N., Tognoni G. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med. 2001; 345 (23):1667 - 1675. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
117. Maggioni A.P., Anand I., Gottlieb S.O. et al. Effects of Valsartan on Morbidity and Mortality in Patients With Heart Failure Not Receiving Angiotensin-Converting Enzyme inhibitors J Am Coll Cardiol. 2002; 40 (8): 1414 - 1421. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
118. McMurray J.J., Ostergren J., Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensin-convertingenzyme inhibitors: the CHARM-Added trial. Lancet. 2003; 362 (9386): 767 - 771. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
119. Konstam M.A., Neaton J.D., Dickstein K. et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009; 374 (9704): 1840 - 1848. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
120. Swedberg K., Komajda M., Bohm M. et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376 (9744): 875 - 885. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
121. Digoxin"s effect on mortality and hospitalization in heart failure: implications of the DIG study. Digitalis Investigation Group. Cleve Clin J Med. 1997 May; 64(5): 234 - 7. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
122. Gheorghiade M., Fonarow G.C., van Veldhuisen D.J. et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J. 2013; 34 (20): 1489 - 1497. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
123. Jorge E., Baptista R., Martins H. et al. Digoxin in advanced heart failure patients: a question of rhythm. Rev Port Cardiol. 2013; 32 (4): 303 - 310. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
124. Gheorghiade M., Patel K., Filippatos G. et al. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail. 2013; 15 (5): 551 - 559. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
125. Rathore S.S., Curtis J.P., Wang Y. et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003; 289 (7): 871 - 878. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
126. Adams K.F., Patterson J.H., Gattis W.A. et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol. 2005; 46 (3): 497 - 504. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
127. The GISSI-HF investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet 2008; 372: 1223 - 30. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
128. Marchioli R., Barzi F., Bomba E. et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell"Infarto Miocardico (GISSI) - Prevenzione. Circulation. 2002; 105(16): 1897 - 1903. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
129. Macchia A., Levantesi G., Franzosi M.G. et al. Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. Eur J Heart Fail. 2005; 7 (5): 904 - 909. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
130. Rauch B., Schiele R., Schneider S., Diller F., Victor N., Gohlke H., Gottwik M., Steinbeck G., Del Castillo U., Sack R., Worth H., Katus H., Spitzer W., Sabin G., Senges J. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010; 122: 2152 - 2159. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
131. Cohn J.N., Archibald D.G., Ziesche S. et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314 (24): 1547 - 1552. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
132. Taylor A.L., Ziesche S., Yancy C. et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004; 351 (20): 2049 - 2057. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
133. Carson P., Ziesche S., Johnson G., Cohn J.N., for the Vasodilator - Heart Failure Trial Study Group. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail 1999; 5 (3): 178 - 187. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
134. Kjekshus J., Dunselman P., Blideskog M. et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics. Eur J Heart Fail 2005; 7 (6): 1059 - 1069. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
135. Tavazzi L., Maggioni A.P., Marchioli R. et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 372 (9645): 1231 - 1239. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
136. Homma S., Thompson J.L., Pullicino P.M. et al, WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012; 366 (20): 1859 - 1869. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
137. Gheorghiade M., 
M., Greene S.J., Fonarow G.C., Lewis E.F., Zannad F., Solomon S.D., Baschiera F., Botha J., Hua T.A., Gimpelewicz C.R., Jaumont X., Lesogor A., Maggioni A.P.; ASTRONAUT Investigators and Coordinators. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA. 2013 Mar 20; 309(11): 1125 - 35. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
138. Parving H.H., Brenner B.M., McMurray J.J., de Zeeuw D., Haffner S.M., Solomon S.D., Chaturvedi N., Persson F., Desai A.S., Nicolaides M., Richard A., Xiang Z., Brunel P., Pfeffer M.A.; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012 Dec 6; 367(23): 2204 - 13. 131. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
139. Komajda M., McMurray J.J., Beck-Nielsen H., Gomis R., Hanefeld M., Pocock S.J., Curtis P.S., Jones N.P., Home P.D. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 2010; 31: 824 - 831. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
140. Hernandez A.V., Usmani A., Rajamanickam A., Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and metaregression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs 2011; 11: 115 - 128. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
141. Erdmann E., Charbonnel B., Wilcox R.G., Skene A.M., Massi-Benedetti M., Yates J., Tan M., Spanheimer R., Standl E., Dormandy J.A. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007; 30: 2773 - 2778. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
142. Goldstein R.E., Boccuzzi S.J., Cruess D., Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation 1991; 83: 52 - 60. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
143. Cohn J.N., Ziesche S., Smith R. et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator - Heart Failure Trial (V-HeFT) Study Group. Circulation. 1997; 96 (3): 856 - 863. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
144. Thackray S., Witte K., Clark A.L., Cleland J.G. Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT. Eur J Heart Fail. 2000; 2(2): 209 - 212. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
145. Packer M., O'Connor C.M., Ghali J.K. et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 1996; 335 (15): 1107 - 1114 (http://www.fesmu.ru/elib/Article.aspx?id=242318)
146. Mamdani M., Juurlink D.N., Lee D.S., Rochon P.A., Kopp A., Naglie G., Austin P.C., Laupacis A., Stukel T.A. Cyclo-oxygenase-2 inhibitors versus non-selective nonsteroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004; 363: 1751 - 1756. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
147. Huerta C., Varas-Lorenzo C., Castellsague J., Garcia Rodriguez L.A. Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population. Heart 2006; 92: 1610 - 1615. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
148. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppressionafter myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med. 1989; 321(6): 406 - 12. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
149. Echt D.S., Liebson P.R., Mitchell L.B., Peters R.W., Obias-Manno D., Barker A.H., Arensberg D., Baker A., Friedman L., Greene H.L., et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991 Mar 21; 324(12): 781 - 8. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
150. McMurray J.J., Packer M., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R., Rouleau JL., Shi V.C., Solomon S.D., Swedberg K., Zile M.R., PARADIGM-HF Investigators andCommittees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. NEngl J Med 2014; 371: 993 - 1004. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
151. Packer M. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation 2002; 106: 2194 - 2199. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
152. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9 - 13. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
153. Wyse D., Friedman P.L., Epstein A.E. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 1997; 337: 1576 - 1583. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
154. Connolly S.J., Hallstrom A.P., Cappato R., Schron E.B., Kuck K.H., Zipes D.P., Greene H.L., Boczor S., Domanski M., Follmann D., Gent M., Roberts R.S. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 2000; 21: 2071 - 2078. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
155. Connolly S.J., Gent M., Roberts R.S., Dorian P., Roy D., Sheldon R.S., Mitchell L.B., Green M.S., Klein G.J., O'Brien B. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101: 1297 - 1302. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
156. Kuck K.H., Cappato R., Siebels J., 
R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102: 748 - 754. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
157. Oseroff O., Retyk E., Bochoeyer A. Subanalyses of secondary prevention implantable cardioverter-defibrillator trials: antiarrhythmics versus implantable defibrillators (AVID), Canadian Implantable Defibrillator Study (CIDS), and Cardiac Arrest Study Hamburg (CASH). Curr Opin Cardiol 2004; 19: 26 - 30. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
158. 
L., Torp-Pedersen C., McMurray J.J.V., 
O., Le'vy S., Crijns H., Amlie J., Carlsen J. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008; 358: 2678 - 2687. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
159. Lafuente-Lafuente C., Valembois L., Bergmann J-F., Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2012; 5: CD005049. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
160. A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Antiarrhythmic Drug Evaluation Group (A.D.E.G.). Eur Heart J 1992; 13: 1251 - 1258. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
161. Bardy G.H., Lee K.L., Mark D.B., Poole J.E., Packer D.L., Boineau R., Domanski M., Troutman C., Anderson J., Johnson G., McNulty S.E., Clapp-Channing N., Davidson-Ray L.D., Fraulo E.S., Fishbein D.P., Luceri R.M., Ip JH. Amiodarone or an implantable cardioverter- defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225 - 237. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
162. Torp-Pedersen C., Metra M., Spark P., Lukas M.A., Moullet C., Scherhag A., Komajda M., Cleland JGF, Remme W., Di Lenarda A., Swedberg K., Poole-Wilson P.A. The safety of amiodarone in patients with heart failure. J Card Fail 2007; 13: 340 - 345. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
163. Chatterjee S., Ghosh J., Lichstein E., Aikat S., Mukherjee D. Meta-analysis of cardiovascular outcomes with dronedarone in patients with atrial fibrillation or heart failure. Am J Cardiol 2012; 110: 607 - 613. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
164. Kirchof P., Benussi S. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016. doi:10.1093/eurheartj/ehw210. Forthcoming. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
165. Pedersen O.D., Bagger H., 
L., Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100: 376 - 380. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
166. Ducharme A., Swedberg K., Pfeffer M.A., CohenSolal A., Granger C.B., Maggioni A.P., Michelson E.L., McMurrayJJ V., Olsson L., Rouleau J.L., Young J.B., Olofsson B., Puu M., Yusuf S. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 152: 86 - 92. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
167. McMurray J., L., Robertson M., Dargie H., Colucci W., Lopez-Sendon J., Remme W., Sharpe D.N., Ford I. Antiarrhythmic effect of carvedilol after acute myocardial infarction. J Am Coll Cardiol 2005; 45: 525 - 530. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
168. Swedberg K., Zannad F., McMurray J.J.V., Krum H., van Veldhuisen D.J., Shi H., Vincent J., Pitt B. Eplerenone and atrial fibrillation in mild systolic heart failure. J Am Coll Cardiol 2012; 59: 1598 - 1603. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
169. Han M., Zhang Y., Sun S., Wang Z., Wang J., Xie X., Gao M., Yin X., Hou Y. Renin-angiotensin system inhibitors prevent the recurrence of atrial fibrillation. J Cardiovasc Pharmacol 2013; 62: 405 - 415. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
170. Martin R.I.R., Pogoryelova O., Koref M.S., Bourke J.P., Teare M.D., Keavney B.D. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart 2014; 100: 1506 - 1510. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
171. Hess P.L., Jackson K.P., Hasselblad V., Al-Khatib S.M. Is cardiac resynchronization therapy an antiarrhythmic therapy for atrial fibrillation? A systematic review and meta-analysis. Curr Cardiol Rep 2013; 15: 330. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
172. Brodsky M.A., Allen B.J., Walker C.J., Casey T.P., Luckett C.R., Henry W.L. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol 1987; 60: 572 - 575. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
173. Deedwania P.C., Singh B.N., Ellenbogen K., Fisher S., Fletcher R., Singh S.N. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 1998; 98: 2574 - 2579. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
174. Shelton R.J., Clark A.L., Goode K., Rigby A.S., Houghton T., Kaye G.C., Cleland JGF. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study). Heart 2009; 95: 924 - 930. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
175. Capucci A., Villani G.Q., Aschieri D., Rosi A., Piepoli M.F. Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. Eur Heart J 2000; 21: 66 - 73. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
176. P. Ponikowski, A.A. Voors, S.D. Anker, H. Bueno, J.G.F. Cleland, A.J.S. Coats, V. Falk, J.' Ramo'n Gonza'lez-Juanatey, V-P. Harjola, E. A. Jankowska, M.iell Jessup, C. Linde, P. Nihoyannopoulos, J. T. Parissis, B. Pieske, J.P. Riley, G.M. C. Rosano, L.M. Ruilope, F. Ruschitzka, F.H. Rutten, P. van der Meer. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure The Task Force for the dianosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). European Heart Journal 2016; 37: 2129 - 2200. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
177. Hofmann R., Steinwender C., Kammler J., Kypta A., Leisch F. Effects of a high dose intravenous bolus amiodarone in patients with atrial fibrillation and a rapid ventricular rate. Int J Cardiol 2006; 110: 27 - 32. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
178. Hofmann R., Wimmer G., Leisch F. Intravenous amiodarone bolus immediately controls heart rate in patients with atrial fibrillation accompanied by severe congestive heart failure. Heart 2000; 84: 635. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
179. Kotecha D., Holmes J., Krum H., Altman D.G., Manzano L., Cleland J.G.F., Lip G.Y.H., Coats A.J.S., Andersson B., Kirchhof P., vonLueder T.G., Wedel H., Rosano G., Shibata M.C., Rigby A., Flather M.D. Efficacy of blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 2014; 384: 2235 - 2243. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
180. Ziff O.J., Lane D.A., Samra M., Griffith M., Kirchhof P., Lip G.Y.H., Steeds R.P., Townend J., Kotecha D. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ 2015; 351: h4451. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
181. Doshi R.N., Daoud E.G., Fellows C., Turk K., Duran A., Hamdan M.H., Pires L.A. PAVE Study Group. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol 2005; 16: 1160 - 1165. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
182. Connolly S.J., Camm A.J., Halperin J.L., Joyner C., Alings M., Amerena J., Atar D., 
, 
P., Borggrefe M., Budaj A., Chen S-A., Ching C.K., Commerford P., Dans A., Davy J-M., 
E., Di Pasquale G., Diaz R., Dorian P., Flaker G., Golitsyn S., Gonzalez-Hermosillo A., Granger C.B., 
H., Kautzner J., Kim J.S., Lanas F., Lewis B.S., Merino J.L., Morillo C., Murin J., Narasimhan C., Paolasso E., Parkhomenko A., Peters N.S., SimK-H., Stiles M.K., Tanomsup S., Toivonen L., 
J., TorpPedersen C., Tse H.F., Vardas P., Vinereanu D., Xavier D., Zhu J-R., Zhu J-R, Baret-Cormel L., Weinling E., Staiger C., Yusuf S., Chrolavicius S., Afzal R., Hohnloser S.H. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011; 365: 2268 - 2276. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
183. Jones D.G., Haldar S.K., Hussain W., Sharma R., Francis D.P., Rahman-Haley S.L., McDonagh T.A., Underwood S.R., Markides V., Wong T. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol 2013; 61: 1894 - 1903. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
184. Khan A.R., Khan S., Sheikh M.A., Khuder S., Grubb B., Moukarbel G.V. Catheter ablation and antiarrhythmic drug therapy as first- or second-line therapy in the management of atrial fibrillation: systematic review and meta-analysis. Circ Arrhythm Electrophysiol 2014; 7: 853 - 860. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
185. Khan M.N., Jais P., Cummings J., Di Biase L., Sanders P., Martin D.O., Kautzner J., Hao S., Themistoclakis S., Fanelli R., Potenza D., Massaro R., Wazni O., Schweikert R., Saliba W., Wang P., Al-Ahmad A., Beheiry S., Santarelli P., Starling R.C., Dello Russo A., Pelargonio G., Brachmann J., Schibgilla V., Bonso A., Casella M., Raviele A., Haissaguerre M., Natale A. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008; 359: 1778 - 1785. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
186. A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Antiarrhythmic Drug Evaluation Group (A.D.E.G.). Eur Heart J 1992; 13: 1251 - 1258. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
187. Dunkman W.B., Johnson G.R., Carson P.E. et al, for the V-HeFT VA Cooperative Studies Group. Incidence of thromboembolic events in congestive heart failure. Circulation. 1993; 87 (6 Suppl): VI94 - 101. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
188. Dunkman W.B. Thromboembolism and antithrombotic therapy in congestive heart failure. J Cardiovasc Risk. 1995; 2 (2): 107 - 117. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
189. Samama M.M., Cohen A.T., Darmon J.Y. et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999; 341 (11): 793 - 800. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
190. Turpie A.G. Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. Am J Cardiol. 2000; 86 (12B): 48M - 52M (http://www.fesmu.ru/elib/Article.aspx?id=242318)
191. Wells Philip S., David R. et al Evaluation of D-Dimer in the Diagnosis of Suspected Deep-Vein Thrombosis N Engl J Med 2003; 349: 1227 - 1235 (http://www.fesmu.ru/elib/Article.aspx?id=242318)
192. National Institute for Health and Clinical Excellence (NICE) clinical guideline. Venous tromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. June 2012 (http://www.fesmu.ru/elib/Article.aspx?id=242318)
193. Vahanian A., et al Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2012; 33: 2451 - 2496. 494. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
194. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt J-U, Simoons ML, Van deWerf F. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369: 1206 - 1214. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
195. D.E., Albers G.W., Dalen J.E. et al. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126 (3 suppl): 429S - 456S. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
196. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factorbased approach: the Euro Heart Survey on atrial fibrillation. Chest 2010; 137: 263 - 272. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
197. Pisters R, Lane DA, Nieuwlaat R. A novel user-friendly score (HAS BLED) to asses 1-year risk of major bleeding in patients with atrial fibrillation. Chest J 2010; 138: 1093 - 1100. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
198. Granger C., Alexander J.H., McMurray J.J. et al, for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365 (11): 981 - 992 (http://www.fesmu.ru/elib/Article.aspx?id=242318)
199. Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361 (12): 1139 - 1151. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
200. Patel M.R., Mahaffey K.W., Garg J. et al. for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365 (10): 883 - 891. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
201. Xiong Q, Lau YC, Senoo K, Lane DA, Hong K, Lip GYH. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. Eur J Heart Fail 2015; 17: 1192 - 1200. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
202. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ, MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003; 5: 659 - 667. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
203. Dorszewski A, 
E, Dorsz'ewski B, Werner GS, Kreuzer H, Figulla HR. Vasodilation by urapidil in the treatment of chronic congestive heart failure in additionto angiotensin-converting enzyme inhibitors is not beneficial: results of a placebo-controlled, double-blind study. J Card Fail 1997; 3: 91 - 96. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
204. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 807 - 816. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
205. Vitale C, Spoletini I, Malorni W, Perrone-Filardi P, Volterrani M, Rosano GMC. Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina-the VASCO-angina study. Int J Cardiol 2013; 168: 1078 - 1081. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
206. Pursnani S, Korley F, Gopaul R, Kanade P, Chandra N, Shaw RE, Bangalore S. Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials. Circ Cardiovasc Interv 2012; 5: 476 - 490. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
207. Panza JA, Holly TA, Asch FM, She L, Pellikka PA, Velazquez EJ, Lee KL, Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet 2009; 373: 911 - 918 (http://www.fesmu.ru/elib/Article.aspx?id=242318)
208. Filippatos G., Farmakis D., Parissis J. Renal dysfunction and heart failure: things are seldom what they seem. Eur Heart J 2014; 35: 416 - 418. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
209. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015; 36: 657 - 668. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
210. Kubo S.H., Walter B.A., John D.H., Clark M., Cody R.J. Liver function abnormalities in chronic heart failure. Influence of systemic hemodynamics. Arch Intern Med 1987; 147:1227 - 1230. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
211. Batin P., Wickens M., McEntegart D., Fullwood L., Cowley A.J. The importance of abnormalities of liver function tests in predicting mortality in chronic heart failure. Eur Heart J 1995; 16: 1613 - 1618. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
212. Rodondi N., Aujesky D., Vittinghoff E., Cornuz J., Bauer D.C. Subclinical hypothyroidism and the risk of coronary heart disease: a meta-analysis. Am J Med. 2006; 119: 541 - 551. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
213. Harjai K.J., Licata A.A. Effects of amiodarone on thyroid function. Ann Intern Med. 2006; 126: 63 - 73. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
214. Buzdar A.U., Marcus C., Smith T.L., et al. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer. 1985; 55(12): 2761 - 5. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
215. Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin. Cancer. 2003; 97(11): 2869 - 79. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
216. Billingham M.E., Mason J.W., Bristow M.R., et al. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 1978; 62(6): 865 - 72. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
217. Diez-Quevedo C., Lupo'n J., Gonza'lez B., Urrutia A., Cano L., Cabanes R., Altimir S., Coll R., Pascual T., de Antonio M., Bayes-Genis A. Depression, antidepressants, and long-term mortality in heart failure. Int J Cardiol 2013; 167: 1217 - 1225. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
218. Ski C.F., Thompson D.R., Hare D.L., Stewart A.G., Watson R. Cardiac Depression Scale: Mokken scaling in heart failure patients. Health Qual Life Outcomes 2012; 10:141 (http://www.fesmu.ru/elib/Article.aspx?id=242318)
219. Lloyd-Jones D., Adams R., Carnethon M. et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119, E21 - E181 (2009). Reports the cardiovascular disease statistics for 2009 in the USA. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
220. Heiat A., Gross C.P., Krumholz H.M. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch. Intern. Med. 2002, (162): 1682 - 1688. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
221. Levy D., Kenchaiah S., Larson M.G. et al.: Long-term trends in the incidence of and survival with heart failure. N. Engl. J. Med. 2002; 347: 1397 - 1402. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
222. Gottdiener J.S., Arnold A.M., Aurigemma G.P. et al.: Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J. Am. Coll. Card. 2000; 35: 1628 - 1637. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
223. Roger V.L., Weston S.A., Redfield M.M. et al.: Trends in heart failure incidence and survival in a community-based population. JAMA 2004; 292: 344 - 350. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
224. Velazquez E.J., Lee K.L., Deja M.A. et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011; 364 (17): 1607 - 1616 (http://www.fesmu.ru/elib/Article.aspx?id=242318)
225. Doenst T., Cleland J.G., Rouleau J.L. et al. Influence of crossover on mortality in a randomized study of revascularization in patients with systolic heart failure and coronary artery disease. Circ Heart Fail. 2013; 6 (3): 443 - 450. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
226. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing andimpact of revascularization on prognosis in patients with coronary artery diseaseand left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002; 39(7): 1151 - 1158. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
227. Cazeau S.,Leclercq C., Lavergne T., Walker S., Varma C., Linde C., Garrigue S., Kappenberger L., Haywood G.A., Santini M., Bailleul C., Mabo P., Lazarus A., Ritter P., Levy T., McKenna W., Daubert J-C. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001; 344: 873 - 880. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
228. Cleland J., Daubert J., Erdmann E., Freemantle N., Gras D., Kappenberger L., Tavazzi L. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539 - 1549. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
229. Cleland JGF, Daubert J-C., Erdmann E., Freemantle N., Gras D., Kappenberger L., Tavazzi L. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J 2006; 27: 1928 - 1932. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
230. Cleland JGF, Freemantle N, Erdmann E, Gras D, Kappenberger L, Tavazzi L, Daubert J-CC. Long-term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization-Heart Failure (CARE-HF) trial. Eur J Heart Fail 2012; 14: 628 - 634. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
231. Bristow M.R., Saxon L.A., Boehmer J., Krueger S., Kass D.A., DeMarco T., Carson P., DiCarlo L., DeMets D., White B.G., DeVries D.W., Feldman A.M. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140 - 2150. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
232. Cleland J.G., Abraham W.T., Linde C., Gold M.R., Young J.B., Claude Daubert J., Sherfesee L., Wells G.A., Tang ASL. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J 2013; 34: 3547 - 3556. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
233. Tang ASL, Wells G.A., Talajic M., Arnold M.O., Sheldon R., Connolly S., Hohnloser S.H., Nichol G., Birnie D.H., Sapp J.L., Yee R., Healey J.S., Rouleau J.L. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010; 363: 2385 - 2395. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
234. Moss A.J., Hall W.J., Cannom D.S., Klein H., Brown M.W., Daubert J.P., Estes NAM, Foster E., Greenberg H., Higgins S.L., Pfeffer M.A., Solomon S.D., Wilber D., Zareba W. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009; 361: 1329 - 1338. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
235. Goldenberg I., Kutyifa V., Klein H.U., Cannom D.S., Brown M.W., Dan A., Daubert J.P., Estes NAM., Foster E., Greenberg H., Kautzner J., Klempfner R., Kuniss M., Merkely B., Pfeffer M.A., Quesada A., Viskin S., McNitt S., Polonsky B., Ghanem A., Solomon S.D., Wilber D., Zareba W., Moss A.J. Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med 2014; 370: 1694 - 1701. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
236. Linde C., Abraham W.T., Gold M.R, St John Sutton M., Ghio S., Daubert C. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008; 52: 1834 - 1843. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
237. Daubert C., Gold MR., Abraham W.T., Ghio S., Hassager C., Goode G., 
T., Linde C., REVERSE Study Group. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE trial. J Am Coll Cardiol 2009; 54: 1837 - 1846. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
238. Linde C., Gold M.R., Abraham W.T., St John Sutton M., Ghio S., Cerkvenik J., Daubert C. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Eur Heart J 2013; 34: 2592 - 2599. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
239. Woods B., Hawkins N., Mealing S., Sutton A., Abraham W.T., Beshai J.F., Klein H., Sculpher M., Plummer C.J., Cowie M.R. Individual patient data network meta-analysis of mortality effects of implantable cardiac devices. Heart 2015; 101: 1800 - 1806. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
240. Curtis A.B., Worley S.J., Adamson P.B., Chung E.S., Niazi I., Sherfesee L., Shinn T, St John Sutton M. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med 2013; 368: 1585 - 1593. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
241. Brignole M., Botto G., Mont L., Iacopino S., De Marchi G., Oddone D., Luzi M., Tolosana J.M., Navazio A., Menozzi C. Cardiac resynchronization therapy in patientsundergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. Eur Heart J 2011; 32: 2420 - 2429. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
242. Leclercq C., Walker S., Linde C., Clementy J., Marshall A.J., Ritter P., Djiane P., Mabo P., Levy T., Gadler F., Bailleul C., Daubert J-C. Comparative effects of permanent biventricular and rightuniventricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J 2002; 23: 1780 - 1787. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
243. Stavrakis S., Garabelli P., Reynolds D.W. Cardiac resynchronization therapy after atrioventricular junction ablation for symptomatic atrial fibrillation: a meta-analysis. Europace 2012; 14: 1490 - 1497. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
244. MacDonald M.R., Connelly D.T., Hawkins N.M., Steedman T., Payne J., Shaw M., Denvir M., Bhagra S., Small S., Martin W., McMurray J.J., Petrie M.C. Radiofrequencyablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. Heart 2011; 97: 740 - 747. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
245. Jones D.G., Haldar S.K., Hussain W., Sharma R., Francis D.P., Rahman-Haley S.L.,McDonagh T.A., Underwood S.R., Markides V., Wong T. A randomized trial to assesscatheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol 2013; 61: 1894 - 1903. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
246. Upadhyay G.A., Choudhry N.K., Auricchio A., Ruskin J., Singh J.P. Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohortstudies. J Am Coll Cardiol 2008; 52: 1239 - 1246. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
247. Gasparini M., Leclercq C., Lunati M., Landolina M., Auricchio A., Santini M., Boriani G., Lamp B., Proclemer A., Curnis A., Klersy C., Leyva F. Cardiac resynchronization therapy in patients with atrial fibrillation. The CERTIFY Study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry). JACC Heart Fail 2013; 1: 500 - 507. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
248. Gage R.M., Burns K.V., Bank A.J. Echocardiographic and clinical response to cardiac resynchronization therapy in heart failure patients with and without previous right ventricular pacing. Eur J Heart Fail 2014; 16: 1199 - 1205. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
249. Ruschitzka F., Abraham W.T., Singh J.P., Bax J.J., Borer J.S., Brugada J., Dickstein K., Ford I., Gorcsan J., Gras D., Krum H., Sogaard P., Holzmeister J. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med 2013; 369: 1395 - 1405. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
250. Steffel J., Robertson M., Singh J.P., Abraham W.T., Bax J.J., Borer J.S., Dickstein K., Ford I., Gorcsan J., Gras D., Krum H., Sogaard P., Holzmeister J., Brugada J., Ruschitzka F. The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. Eur Heart J 2015; 36: 1983 - 1989. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
251. Zusterzeel R., Selzman K.A., Sanders W., 
D.A., O'Callaghan K.M., Carpenter J.L., 
I.L., Strauss D.G. Cardiac resynchronization therapy in women:US Food and Drug Administration meta-analysis of patient-level data. JAMA Intern Med 2014; 174: 1340 - 1348. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
252. Connolly S.J., Gent M., Roberts R.S., Dorian P., Roy D., Sheldon R.S., Mitchell L.B., Green M.S., Klein G.J., O"Brien B. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101: 1297 - 1302. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
253. Moss A.J., Zareba W., Hall W.J., Klein H., Wilber D.J., Cannom D.S., Daubert J.P., Higgins S.L., Brown M.W., Andrews M.L. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877 - 883. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
254. Desai A.S., Fang J.C., Maisel W.H., Baughman K.L. Implantable-defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA 2004; 292: 2874 - 2879. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
255. Sanders G.D., Hlatky M.A., Owens D.K. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005; 353: 1471 - 1480. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
256. Kadish A., Dyer A., Daubert J.P., Quigg R., Estes NAM., Anderson K.P., Calkins H., Hoch D., Goldberger J., Shalaby A., Sanders W.E., Schaechter A., Levine J.H. Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350: 2151 - 2158. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
257. Bardy G.H., Lee K.L., Mark D.B., Poole J.E., Packer D.L., Boineau R., Domanski M., Troutman C., Anderson J., Johnson G., McNulty S.E., Clapp-Channing N., Davidson-Ray L.D., Fraulo E.S., Fishbein D.P., Luceri R.M., Ip J.H. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225 - 237. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
258. Hohnloser S.H., Kuck K.H., Dorian P., Roberts R.S., Hampton J.R., Hatala R., Fain E., Gent M., Connolly S.J. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004; 351: 2481 - 2488. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
259. Teinbeck G., Andresen D., Seidl K., Brachmann J., Hoffmann E., Wojciechowski D., Kornacewicz-Jach Z., Sredniawa B., Lupkovics G., Hofgrtner F., Lubinski A., RosenqvistM., HabetsA., Wegscheider K., Senges J. Defibrillator implantation early after my ocardialinfarction. N Engl J Med 2009; 361: 1427 - 1436. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
260. 260 Steinberg B.A., AlKhatib S.M., Edwards R., Han J., Bardy G.H., Bigger J.T., Buxton A.E., Moss A.J., Lee K.L., Steinman R., Dorian P., Hallstrom A., Cappato R., Kadish A.H., Kudenchuk P.J., Mark D.B., Inoue LYT, Sanders G.D. Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials. JACC Heart Fail 2014; 2: 623 - 629. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
261. Raphael C.E., Finegold J.A., Barron A.J., Whinnett Z.I., Mayet J., Linde C., Cleland JGF., Levy W.C., Francis D.P. The effect of duration of follow-up and presence of competing risk on lifespangain from implantable cardioverter defibrillator therapy: who benefits the most? Eur Heart J 2015; 36: 1676 - 1688. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
262. Miller RJH., Howlett J.G., Exner D.V., Campbell P.M., Grant ADM., Wilton S.B. Baseline functional class and therapeutic efficacy of common heart failure interventions: a systematic review and meta-analysis. Can J Cardiol 2015; 31: 792 - 799. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
263. Hess P.L., AlKhatib S.M., Han J.Y., Edwards R., Bardy G.H., Bigger J.T., Buxton A., Cappato R., Dorian P., Hallstrom A., Kadish A.H., Kudenchuk P.J., Lee K.L., Mark D.B., Moss A.J., Steinman R., Inoue LYT, Sanders G. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials. Circ Cardiovasc Qual Outcomes 2015; 8: 179 - 186. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
264. Merchant F.M., Jones P., Wehrenberg S., Lloyd M.S., Saxon L.A. Incidence of defibrillator shocks after elective generator exchange following uneventful first battery life. J Am Heart Assoc 2014; 3:e001289. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
265. Yap S-C., Schaer B.A., Bhagwandien R.E., Kuhne M., Dabiri Abkenari L., Osswald S., Szili-Torok T., Sticherling C., Theuns D.A. Evaluation of the need of elective implantable cardioverter-defibrillator generator replacement in primary prevention patients without prior appropriate ICD therapy. Heart 2014; 100: 1188 - 1192. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
266. Kini V., Soufi M.K., Deo R., Epstein A.E., Bala R., Riley M., Groeneveld P.W., Shalaby A., Dixit S. Appropriateness of primary prevention implantable cardioverter-defibrillators at the time of generator replacement: are indications still met? J Am Coll Cardiol 2014; 63: 2388 - 2394. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
267. Erkapic D., Sperzel J., Stiller S., Meltendorf U., Mermi J., Wegscheider K., 
B. Long-term benefit of implantable cardioverter/defibrillator therapy after elective device replacement: Results of the INcidence free SUrvival after ICD REplacement (INSURE) trial-a prospective multicentre study. Eur Heart J 2013; 34: 130 - 137. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
268. Alsheikh-Ali A.A., Homer M., Maddukuri P.V., Kalsmith B., Estes NAM, Link M.S. Time-dependence of appropriate implantable defibrillator therapy in patients with ischemic cardiomyopathy. J Cardiovasc Electrophysiol 2008; 19: 784 - 789. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
269. Opreanu M., Wan C., Singh V., Salehi N., Ahmad J., Szymkiewicz S.J., Thakur R.K. Wearable cardioverter-defibrillator as a bridge to cardiac transplantation: a national database analysis. J Heart Lung Transplant 2015; 34: 1305 - 1309. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
270. Zishiri E.T., Williams S., Cronin E.M., Blackstone E.H., Ellis S.G., Roselli E.E., Smedira N.G., Gillinov A.M., Glad J.A., Tchou P.J., Szymkiewicz S.J., Chung M.K. Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator. Circ Arrhythm Electrophysiol 2013; 6: 117 - 128. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
271. Chung M.K., Szymkiewicz S.J., Shao M., Zishiri E., Niebauer M.J., Lindsay B.D., Tchou PJ. Aggregate national experience with the wearable cardioverter-defibrillator. J Am Coll Cardiol 2010; 56: 194 - 203. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
272. Stewart G.C., Givertz M.M. Mechanical circulatory support for advanced heart failure: patients and technology in evolution. Circulation 2012; 125: 1304 - 1315. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
273. Schmidt M., Burrell A., Roberts L., Bailey M., Sheldrake J., Rycus P.T., Hodgson C., Scheinkestel C., Cooper D.J., Thiagarajan R.R., Brodie D., Pellegrino V., Pilcher D. Predictingsurvival after ECMO for refractory cardiogenic shock: the survival afterveno-arterial-ECMO (SAVE)-score. Eur Heart J 2015; 36: 1 - 11; (http://www.fesmu.ru/elib/Article.aspx?id=242318)
274. Riebandt J., Haberl T., Mahr S., Laufer G., Rajek A., Steinlechner B., Schima H., Zimpfer D. Preoperative patient optimization using extracorporeal life supportimproves outcomes of INTERMACS level I patients receiving a permanent ventricularassist device. Eur J CardiothoracSurg 2014; 46: 486 - 492; (http://www.fesmu.ru/elib/Article.aspx?id=242318)
275. Cheng J.M., den Uil C.A., Hoeks S.E., van der Ent M., Jewbali L.S.D., van Domburg R.T., Serruys P.W. Percutaneous left ventricular assist devices vs. intra-aortic balloonpump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. Eur Heart J 2009; 30: 2102 - 2108; (http://www.fesmu.ru/elib/Article.aspx?id=242318)
276. O'Neill W.W., Kleiman N.S., Moses J., Henriques J.P.S., Dixon S., Massaro J., Palacios I., Maini B., Mulukutla S., 
V., Popma J., Douglas P.S., Ohman M. A prospective, randomized clinical trial of hemodynamic support with impella 2.5 versusintra-aortic balloon pump in patients under going high-risk percutaneous coronaryintervention: the PROTECT II study. Circulation 2012; 126: 1717 - 1727; (http://www.fesmu.ru/elib/Article.aspx?id=242318)
277. Rahmel A, ed. Eurotransplant International Foundation Annual Report 2013. Leiden, The Netherlands: CIP-GegevensKoninklijkeBibliotheek, 2013; (http://www.fesmu.ru/elib/Article.aspx?id=242318)
278. Trivedi J.R., Cheng A., Singh R., Williams M.L., Slaughter M.S. Survival on the hearttransplant waiting list: impact of continuous flow left ventricular assist device asbridge to transplant. Ann ThoracSurg 2014; 98: 830 - 834; (http://www.fesmu.ru/elib/Article.aspx?id=242318)
279. Birks E.J., Tansley P.D., Hardy J., George R.S., Bowles C.T., Burke M., Banner N.R., Khaghani A., Yacoub M.H. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 2006; 355: 1873 - 1884; (http://www.fesmu.ru/elib/Article.aspx?id=242318)
280. Dandel M., Knosalla C., Hetzer R. Contribution of ventricular assistdevices to therecovery of failing hearts: a review and the Berlin Heart Center Experience. Eur JHeart Fail 2014; 16: 248 - 263; (http://www.fesmu.ru/elib/Article.aspx?id=242318)
281. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure European Heart Journal (2016) 37, 2129 - 2200 doi: 10. 1093/eurheartj/ehw128; (http://www.fesmu.ru/elib/Article.aspx?id=242318)
282. Estep J., Starling R.C., Horstmanshof D.A., Milano C.A., SelzmanC.H., Shah K.B.,Loebe M., Moazami N., Long J.W., Stehlik J., Kasirajan V., Haas D.C., O'Connell J.B.,Boyle A.J., Farrar D.J., Rogers J.G. Risk assessment and comparative effectiveness ofleft ventricular assist device and medical management in ambulatory heart failurepatients: results from the ROADMAP study. J AmCollCardiol 2015; 66: 1747 - 1761; (http://www.fesmu.ru/elib/Article.aspx?id=242318)
283. Rose E.A., Gelijns A.C., Moskowitz A.J., Heitjan D.F., Stevenson L.W., Dembitsky W., Long J.W., Ascheim D.D., Tierney A.R., Levitan R.G., Watson J.T., Meier P., Ronan N.S., Shapiro P.A., Lazar R.M., Miller L.W., Gupta L., Frazier O.H., Desvigne-Nickens P., Oz M.C., Poirier V.L. Long-term use of a left ventricular assistdevice for end stage heart failure. N Engl J Med 2001; 345: 1435 - 1443; (http://www.fesmu.ru/elib/Article.aspx?id=242318)
284. Slaughter M.S., Rogers J.G., Milano C.A., Russell S.D., Conte J.V., Feldman D., Sun B., Tatooles A.J., Delgado R.M., Long J.W., Wozniak T.C., Ghumman W., Farrar D.J., Frazier O.H. Advanced heart failure treated with continuous-flow left ventricularassist device. N Engl J Med 2009; 361: 2241 - 2251; (http://www.fesmu.ru/elib/Article.aspx?id=242318)
285. Slaughter M.S., Rogers J.G., Milano C.A. et al. Advanced heart failuretreated with continuous-flow left ventricular assist device. N Engl J Med. 2009; 361 (23): 2241 - 2251. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
286. O'Connor C.M., Whellan D.J., Lee K.L., Keteyian S.J., Cooper L.S., Ellis S.J., Leifer E.S.,Kraus W.E., Kitzman D.W., Blumenthal J.A., Rendall D.S., Miller N.H., Fleg J.L.,Schulman K.A., McKelvie R.S., Zannad F., I.L., HF-ACTION Investigators. Efficacyand safety of exercise training in patients with chronic heart failure: HF-ACTIONrandomized controlled trial. JAMA 2009; 301: 1439 - 1450. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
287. Taylor RS, Sagar VA, Davies EJ, Briscoe S, Coats AJ, Dalal H, Lough F, Rees K, Singh S. Exercise-based rehabilitation for heart failure. Cochrane Database Syst Rev 2014; 4: CD003331. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
288. Nolte K, Herrmann-Lingen C, Wachter R, Gelbrich G, Dungen H-D, Duvinage A, Hoischen N, Von Oehsen K, Schwarz S, Hasenfuss G, Halle M, Pieske B, Edelmann F. Effects of exercise training on different quality of life dimensions in heart failure with preserved ejection fraction: the Ex-DHF-P trial. Eur J Prev Cardiol 2015; 22: 582 - 593. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
289. Ismail H, McFarlane JR, Nojoumian AH, Dieberg G, Smart NA. Clinical outcomes and cardiovascular responses to different exercise training intensities in patients with heart failure: a systematic review and meta-analysis. JACC Heart Fail 2013; 1: 514 - 522. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
290. Feltner C, Jones CD, Cene' CW, Zheng Z-J, Sueta CA, Coker-Schwimmer EJLL, Arvanitis M, Lohr KN, Middleton JC, Jonas DE. Transitional care interventions to prevent readmissions for persons with heart failure: a systematic review and meta-analysis. Ann Intern Med 2014; 160: 774 - 784. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
291. McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol 2004; 44: 810 - 819. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
292. Phillips CO, Wright SM, Kern DE, Singa RM, Shepperd S, Rubin HR. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. JAMA 2004; 291: 1358 - 1367. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
293. Stewart S, Vandenbroek AJ, Pearson S, Horowitz JD. Prolonged beneficial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure. Arch Intern Med 1999; 159: 257 - 261. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
294. Schou M, Gustafsson F, Videbaek L, Tuxen C, Keller N, Handberg J, Sejr Knudsen A, Espersen G, Markenvard J, Egstrup K, Ulriksen H, Hildebrandt PR. Extended heart failure clinic follow-up in low-risk patients: a randomized clinical trial (NorthStar). Eur Heart J 2013; 34: 432 - 442. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
295. Luttik MLA, Jaarsma T, van Geel PP, Brons M, Hillege HL, Hoes AW, de Jong R, Linssen G, Lok DJA, Berge M, van Veldhuisen DJ. Longterm follow-up in optimally treated and stable heart failure patients: primary care vs. heart failure clinic. Results of the COACH-2 study. Eur J Heart Fail 2014; 16: 1241 - 1248. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
296. Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, Strickland W, Neelagaru S, Raval N, Krueger S, Weiner S, Shavelle D, Jeffries B, Yadav JS. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 2011; 377: 658 - 666. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
297. Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete followup results from the CHAMPION randomised trial. Lancet 2016; 387: 453 - 461. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
298. Hindricks G, Taborsky M, Glikson M, Heinrich U, Schumacher B, Katz A, Brachmann J, Lewalter T, Goette A, Block M, Kautzner J, Sack S, Husser D, Piorkowski C, S gaard P. Implant-based multiparameter telemonitoring of patients with heart failure (INTIME): a randomised controlled trial. Lancet 2014; 384: 583 - 590. (http://www.fesmu.ru/elib/Article.aspx?id=242318)
- Гражданский кодекс (ГК РФ)
- Жилищный кодекс (ЖК РФ)
- Налоговый кодекс (НК РФ)
- Трудовой кодекс (ТК РФ)
- Уголовный кодекс (УК РФ)
- Бюджетный кодекс (БК РФ)
- Арбитражный процессуальный кодекс
- Конституция РФ
- Земельный кодекс (ЗК РФ)
- Лесной кодекс (ЛК РФ)
- Семейный кодекс (СК РФ)
- Уголовно-исполнительный кодекс
- Уголовно-процессуальный кодекс
- Производственный календарь на 2025 год
- МРОТ 2025
- ФЗ «О банкротстве»
- О защите прав потребителей (ЗОЗПП)
- Об исполнительном производстве
- О персональных данных
- О налогах на имущество физических лиц
- О средствах массовой информации
- Производственный календарь на 2024 год
- Федеральный закон "О полиции" N 3-ФЗ
- Расходы организации ПБУ 10/99
- Минимальный размер оплаты труда (МРОТ)
- Календарь бухгалтера на 2025 год
- Частичная мобилизация: обзор новостей